Endothei-1 (ET-I) levels are elvated in human breast tumours compared with normal and benign tissues, and in the presence of insuin-hlke growth factor I (IGF-I) ET-I is a potent mitogen for human breast fibroblasts. In this study we have examied the ability of intact human breast cancer cell lines to process exogenously added big ET-I (1 -38) to the active mature ET-I peptide by using a specific radioimmu assay. In both hormome-dpendent (MCF-7, T47-D) and hormone-independent (MDA-MB-231) breast cancer cell lnes the putative endothehn-converting enzyme (ECE) exhibited apparent Mxichalis-Menten kinetics when converting added big ET-I to ET-I. Both basal ET-I production and exogenously added big ET-I to ET-I convesion were greatly reduced m all three cel lines in response to the metalloproteinase inhibitor phosphoramidon but were insensitive to other classes of protease inhibitors. Inhibition was also observed when cells were incubated in the presence of the divalent cation chelators 1,10-phenanthrohn and EDTA. In MCF-7 cells the optimal pH for the ECE activity using a saponin cell permeabilisation procedure was found to reside within a narrow range of 6.2-726. Our results indicate that human breast cancer cells contain a neutral phosphoramidon-sensitive metalloproteinase which can process big ET-i to ET-I. In the breast this converson could contnbute substantially to the local extracellular kvels of this proposed paracrie breast fibroblast mitogen.
Since the discovery of the potent vasoconstrictor ET-I from the spent medium of porcine aortic endothelial cells (Yanagisawa et al., 1988) other interesting facets relating to this peptide have emerged. It is now known that ET-1 is expressed and produced by both vascular and non-vascular cell types. Indeed, several human tumour cell lines derived from the breast, colon, pancreas (Kusuhara et al., 1990) , endometrium (Economos et al., 1992) , cervix and larynx (Shichiri et al., 1991) also release immunoreactive ET. Such a wide range of cell types expressing ET-1 peptide suggests that it probably has diverse physiological actions. In addition to its role in the vasculature, where it regulates blood pressure by modulating vascular tonus, ET-1 also promotes steroidogenesis in Leydig tumour cells (Ergul et al., 1993) , stimulates the secretion of aldosterone (Cozza et al., 1989) , noradrenaline and adrealine (Boarder and Marriott, 1991) , inhibits renin release from the glomerulus (Rakugi et al., 1988) and promotes proliferation in a number of cell types (Battistini et al., 1993a) .
Studies which have examined the sites of ET-l expression and binding indicate that ET-1 acts predominantly as an endocrine/paracrine mediator since in some tissues only ET-1 receptors are present while in other tissues ET-l-producing cells are found adjacent to ET-1 receptor-expressing cells. For instance, in breast tissue the epithelial cells express ET-1 whereas breast fibroblasts possess endothelin receptors (Baley et al., 1990) . Thus, the ET-1 released from the breast epithelial cells may act in a paracrine fashion on neighbouring stromal tissue. An autocrine action of ET-1 has also been recently suggested by Shichiri et al. (1991) , who found that two ET-l-producing epithelial cancer cell lines could be mitogenically stimulated by the addition of ET-1 and inhibited by an endothelin polyclonal antibody.
Molecular studies involving screening the human genomic DNA library have revealed the presence of a family of ET-1 related peptides (ET-1, -2 and -3), all 21 amino acids in length. It appears that all three isopeptides are encoded by distinct genes on separate chromosomes (Inoue et al., 1989) . Evidence suggests that these ET-1 peptides are regulated independently in a tissue-specific manner (Rubanyi and Parker-Botelho, 1991) . From the predicted prepro-ET-1 sequence, together with the known amino acid sequence of big ET-1 (1-38), the processing steps for the production of mature ET-1 have been proposed. Initialy the conversion of the 212 amino acid prepro-ET-1 to big ET-1 is thought to involve a pair of dibasic endopeptidases and carboxypeptidases. This is followed by the conversion of big ET-1 to ET-1 by an unidentified putative ECE which catalyses an unusual proteolytic cleavage between the Trp-21 and Val-22 bond of big ET-1. This unusual processing step has also been reproduced in heterologous systems, such as in COS (Dilella et al., 1991) and baculovirus-infected insect cells (Benatti et al., 1992) .
To date several candidates for this putative ECE have been proposed. These include the cathepsin D-like (Sawamura et al., 1990) or cathepsin E-like aspartic protease (Lees et al., 1990) , the soluble phosphoramidon-sensitive (Takada et al., 1991) and -insensitive metalloproteinase (Matsumura et al., 1991) and a membrane-bound phosphoramidon-sensitive metalloproteinase (Ohnaka et al., 1993) . From these and numerous other studies conducted so far the emphasis now appears to be directed towards the neutral phosphoramidonsensitive metalloproteinase described by Ohnara et al. (1993) as being the likely physiologically relevant enzyme involved in big ET-1 processing. An ECE from rat endothelial cells has been recently cloned and functionally expressed (Shimada et al., 1994) and has properties coinciding with those of the enzyme from porcine aortic endothelium (Ohnaka et al., 1993) . The subcellular location of this ECE is at present uncertain. A recent report shows that the majority of the membrane-bound phosphoramidon-sensitive ECE in rat lung is located in the Golgi complex (Gui et al., 1994) , consistent with a role in intracellular processing. However, a similar ECE in the endothelial cell line EAHY 926 is present in the plasma membrane (Waxman et al., 1994) .
We report here studies conducted to identify and charactense the human breast cancer cell ECE (BCC-ECE), which can process big ET-1 to ET-1, a 'competence-type' growth factor for human breast fibroblasts (Schrey et al., 1992 (Figure 1) . Thus, at 1 h the ET-1 produced from exogenous big ET-1 was 125% greater than basal release, while at 24h this increase had risen by 320%.
To evaluate the differences in the conversion rates of big ET-1 to ET-1 in the various cell lines, we studied the kinetics of the ECE-mediated catalysis using intact cells. Under the experimental conditions used the putative ECE in the MCF-7, T47-D and MDA-MB-231 cell lines followed MichaelisMenten kinetics (Figure 2 (Ca2+ 1.8 mM) , it was found that in three separate experiments both EDTA and 1,10-phenanthroline greatly reduced both basal ET-1 production and added big ET-1 to ET-1 conversion ( Figure 5 ). 1,10-Phenanthroline attenuated the conversion of big ET-1 to ET-1 in a dose-related manner, and at the highest concentration examined (200 pM) a 38% inhibition was observed, while EDTA (1 mM) completely abolished big ET-1 processing. Again at the concentrations Phophor donI-seuilwe metlop oinase in hmman eas cuw cels KV Patel and MP Schrey 445 examined cell viability and cell numbers were not significantly affected from untreated cells over the 24 h incubation period.
The optimal pH for the BCC-ECE activity was examined by incubating saponin-permeabilised cells with big ET-1 in the absence and presence of phosphoramidon (10 1M). Our results clearly show that the optimal pH for the putative BCC-ECE under our experimental conditions resided within a narrow range of 6.20-7.26 ( Figure 6 ). Furthermore, this activity was significantly attenuated by phosphoramidon. Therefore, this enzyme appears to belong to the neutral metalloproteinase class of enzymes which is sensitive to phosphoramidon. (Okada et al., 1990 ) and rat lung (Takahashi et al., 1993) . That is to say this activity was inhibited by metal chelators and phosphoramidon but was insensitive to other classes of enzyme inhibitors, including pepstatin A, an inhibitor of cathepsin D, an acidic protease implicated in big ET-l processing in some systems (Sawamura et al., 1990) and thiorphan, another inhibitor of neutral (metallo) endopeptidase. Furthermore, the optimal pH for the BCC-ECE was determined to be between 6.2 and 7.2 which agrees with 7.0 7.5 8.0
recent studies on other cell types (Okada et al., 1990; Takahashi et al., 1993; Waxman et al., 1994) . n permeabilised Michaelis-Menten kinetics on intact cells revealed that the n to near confluence in MCF-7 and T47-D cell lines had a 2-fold greater affinity for saponin (Gleiber and Schiffman, 1984; Horgan et al., 1987) and in vitro conditions (Mukaida et al., 1991; van Roozendall et al., 1992; Ryan et al., 1993) , suggesting a paracrine mode of action. Such an effect may be due partly to the secretion of stimulatory fibroblast-derived growth factors such as IGF-I and IGF-II. Indeed, IGF-I, a mitogen for breast cancer cells, has been shown to be produced by human fibroblasts in vitro (Clemmons, 1984; Ankrapp and Bevan, 1993) and is expressed by breast stromal cells but not epithelial cells (Yee et al., 1989) . Moreover, Cullen et al. (1991) (Paik, 1992) . Interestingly, in placental fibroblasts ET-1 has been shown to stimulate the production of IGF-II and IGF-binding proteins, but not IGF-I (Fant et al., 1992) . Thus, the high levels of ET-1 found in malignant breast tumour tissue may be instrumental in the increased IGF-II expression observed in the fibroblasts surrounding these tumours.
In the context of such a paracrine loop the bioavailability of ET-1 may represent an important event through which breast fibroblasts regulate the function of the breast epithelial cells. Therefore, the potential sources of ET-1 need to be examined. In this respect, breast epithelial cells are a known source of ET-1, and under in vitro conditions basal ET-1 levels can be augmented in response to prolactin (Baley et al., 1990) , glucocorticoids, bombesin (Schrey et al., 1992) and interleukin 6 (Yamashita et al., 1993) . Endothelin-l may be also sequestered from the circulation, where concentrations of 1.5 pM have been measured (Battistini et al., 1993b) , since in post-colostrum lactating mothers the levels of ET-1 in milk are at least 1 -fold higher than that found in plasma (Lam et al., 1990) , consistent with an active uptake mechanism. Finally, the ratio of big ET-1 to ET-1 found in the circulation on average is generally found to be 2-4 (Battistini et al., 1993b) . and, assuming an active uptake mechanism, this precursor then represents a readily available source of the BCC-ECE.
In summary. we have identified in breast cancer cells the presence of a phosphoramidon-sensitive neutral metalloproteinase which can process big ET-I to the breast fibroblast mitogen ET-I. Thus, this enzyme may represent a therapeutic target for those breast tumours, in which the stromal component is important in the growth of the tumour. 
